SECURITIES
      AND EXCHANGE COMMISSION


WASHINGTON,
      DC 20549





FORM
      10-KSB/A


(Amendment
      No. 2)





[X]
      ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF


THE
      SECURITIES EXCHANGE ACT OF 1934


For
      the
      fiscal year ended December 31, 2004





COMMISSION
      FILE NO. 333-57946





OR





[
      ]
      TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF


THE
      SECURITIES EXCHANGE ACT OF 1934


For
      the
      transition period from ______to______








INHIBITON
      THERAPEUTICS, INC.


(Name
      of
      Small Business Issuer as specified in its charter)





NEVADA
            88-0448626(State
                or Other Jurisdiction of
            (IRS
                EmployerIncorporation
                or Organization)
            Identification
                No.)





7315
      EAST PEAKVIEW AVENUE, ENGLEWOOD, COLORADO 80111


(Address
      of Principal Executive Offices and Zip Code)





(303)
      796-8940


(Issuer's
      Telephone Number)





NONE


(Securities
      registered under Section 12(b) of the Act)


NONE


(Securities
      registered under Section 12(g) of the Act)





Check
      whether the issuer (1) filed all reports required to be filed by sections 13
      or
      15(d) of the Exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports), and (2) has been subject
      to such filing requirements for the past 90 days. Yes [X] No [ ]





Check
      if
      disclosure of delinquent filers pursuant to Item 405, of Regulation S-B is
      not
      contained in this form, and no disclosure will be contained, to the best of
      registrant's knowledge, in definitive proxy or information statements
      incorporated by reference in Part III of this Form 10-KSB/A or any amendment
      to
      this Form 10-KSB/A. [ ]





Registrant's
      revenue for its most recent fiscal year: $0.





The
      Company's voting securities are traded on the Over the Counter (OTC) Electronic
      Bulletin Board under the symbol IBHT. There was a minimal market and very
      limited trading volume for the issuer's common stock during fiscal year 2004.
      The aggregate market value of the voting common equity securities held by
      non-affiliates of the Registrant was $1,839,830 on June 20, 2006 based upon
      the
      closing price of the Registrant's Common Stock on that date
      ($0.36).





As
      of
      June 20, 2006, there were 13,451,000 shares of common stock of the registrant
      outstanding, par value $.001.





Transitional
      Small Business Format: Yes [ ] No [ X ]





Documents
      incorporated by reference: None.





EXPLANATORY
      NOTE





Inhibiton
      Therapeutics, Inc. (formerly known as Organic Soils.Com, Inc.) (the
“Registrant”) is filing this Amendment No. 2 (this “Amendment”) to its Annual
      Report on Form 10-KSB for the fiscal year ended December 31, 2004, which was
      originally filed with the Securities and Exchange Commission (the “SEC”) on
      February 24, 2005 (the “Annual Report”), and amended on March 7, 2005, solely
      for the purpose of correcting errors in the signature portion of the Report
      of
      Registered Independent Public Accounting Firm to include the correct signature,
      date, and city and state of domicile for such Registered Independent Public
      Accounting Firm..




This
      Amendment does not reflect events occurring after the filing of the Annual
      Report or any previous amendments thereto, or modify or update those disclosures
      affected by subsequent events. Except for the items described above or contained
      in this Amendment, this Amendment continues to speak as of the date of the
      Annual Report or any amendments thereto, and does not modify, amend or update
      in
      any way the financial statements or any other item or disclosures in the Annual
      Report.














**SIGNATURES**





In
      accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused
      this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.








INHIBITON
                THERAPEUTICS, INC.(Registrant)Date:June
                23, 2006
            By:*/s/
                Henry Fong*Henry
                FongPresident,
                Chief Executive Officer and
              Chief
                Financial Officer











In
      accordance with the Exchange Act, this report has been signed below by the
      following persons on behalf of the registrant and in the capacities and on
      the
      dates indicated.











Date:June
                23, 2006
            */s/
                Henry Fong*Henry
                FongDirector











HAWKINS
      ACCOUNTING


Certified
      Public Accountant


Audit
      .
      tax . consulting







**To
      the Board of Directors and Shareholders**


Organic
      Soils.com, Inc.


Anchorage,
      Alaska





**Report
      of Independent Registered Public Accounting Firm**







I
      have
      audited the balance sheet of Organic Soils.com, Inc. as of December 31, 2004
      and
      the related statements of operations, stockholders’ equity and cash flows for
      the year ended December 31, 2004. These financial statements are the
      responsibility of the Company’s management. My responsibility is to express an
      opinion on these financial statements based on my audit.




I
      conducted my audit in accordance with the standards of the Public Company
      Accounting Oversight Board (United States). Those standards require that I
      plan
      and perform the audit to obtain reasonable assurance about whether the financial
      statements are free of material misstatement. An audit includes examining,
      on a
      test basis, evidence supporting the amounts and disclosures in the financial
      statements. An audit also includes assessing the accounting principles used
      and
      significant estimates made by management, as well as evaluating the overall
      financial statement presentation. I believe that my audit provides reasonable
      basis for my opinion.




In
      my
      opinion, the financial statements referred to above present fairly, in all
      material respects, the financial position of Organic Soils.com as of December
      31, 2004, the results of operations and it’s cash flows for the year then ended
      in conformity with generally accepted accounting principles in the United States
      of America.




As
      discussed in Note 4 the accompanying financial statements have been prepared
      assuming that the Company will continue as a going concern. The Company has
      a
      working capital deficiency of $43,330 and shareholders’ deficiency of $43,330 at
      December 31, 2004, and a net loss from operation of $15,671 and a negative
      cash
      flow from operations of $13,639 for 2004, which raises substantial doubt about
      its ability to continue as a going concern. The financial statements do not
      include any adjustment that might result from the outcome of this
      uncertainty.







/s/
      Hawkins Accounting




January
      26, 2005


Los
      Angeles, California







3535
      S.
      Bentley Ave. Suite 302 Los Angeles, CA 90064


408.460.4173
      FAX 310.477.6040 RRH2CPA@CS.COM